ITC Rules Against Apple in Samsung Patent Infringement Case

Michael Teague |

AppleThe U.S. International Trade Commission issued its much awaited ruling on a patent infringement case brought by Korean electronics giant Samsung against its bitter mobile rival Apple (AAPL) on Tuesday.
The ITC ruled against Apple in the case, agreeing that the company had indeed infringed on a data transmission patent owned by Samsung. Apple could be slapped with a ban on imports of different models of the iPhone 3 and 4, as well as the iPad 2 and 3G that the company made for AT&T (T). All import bans in the U.S. are subject to approval by the president, and Apple will be able to continue selling the aforementioned products for the duration of the 60 days that president Obama has to either accept or veto the ruling.
Both companies have squared off in court over the issue of patent infringement in the past as Samsung tries to enhance its increasingly dominant position in the $293 billion-a-year mobile market, and Apple tries to preserve what remains of its former dominance in that space. Last August, Apple won a $1 billion settlement over infringement against the Korean firm, at least $599 million of which will definitely have to pay.
That decision, however, did not block the sale of Samsung’s products as did Tuesday’s ruling against Apple. While Samsung has quickly taken over as the world’s largest maker of smart phones, Apple still dominates the market in the U.S., so the decision could be significant for the rivalry between the two. Together, both firms account for over half of the world’s smart phones.
Meanwhile, Apple is still waiting for an ITC ruling on another case it has against Samsung, which should be decided on the 1st of August. Apple has accused Samsung of having copied the look and feel of its own products in their Android-based Galaxy line of phones.
Other than a veto of the decision by president Obama, Apple would also have recourse to the federal appeals process to reverse the decision.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Symbol Name Price Change % Volume
AAPL Apple Inc. 165.24 -0.48 -0.29 36,515,477 Trade
GOOG Alphabet Inc. 1,067.45 -5.51 -0.51 2,341,258 Trade
T AT&T Inc. 34.89 0.22 0.63 21,211,939 Trade
DBVT DBV Technologies S.A. 23.28 -0.47 -1.98 105,075 Trade


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets


Voleo is a free download that allows you to form investment clubs with your friends, family, colleagues, classmates, teammates…basically anyone you know and trust. Invest and manage a stock portfolio…

The Green Organic Dutchman

The Green Organic Dutchman Ltd. ("TGOD") produces farm grown, organic cannabis for medical use. The company grows its high quality organic cannabis in small batches using craft growing, all natural…